Guan-Yi Li

Guan-Yi Li

Auto-generated profile, based on publicly available information

Guan-Yi Li

Department of Medicine, National Yang-Ming Chiao-Tung University School of Medicine, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
GLGuan-Yi Li
Guan-Yi Li
Yun-Yu ChenYun-Yu Chen
Yun-Yu Chen
LYLin Yenn-jiang
Lin Yenn-jiang
KCKuo-Liong Chien
Kuo-Liong Chien
YHYu-Cheng Hsieh
Yu-Cheng Hsieh
SCShih-Ann Chen
Shih-Ann Chen
This study investigated the epidemiological characteristics of new-onset dementia in patients with atrial fibrillation (AF) and the association of catheter ablation with different subtypes of dementia. We conducted a population-based, retrospective cohort study using data from the Taiwan National Health Insurance Research Database. In total, 136 774 patients without a history of dementia were selected after 1:1 propensity score matching based on age (with AF vs. without AF). A competing risk model was used to investigate the three subtypes of dementia: Alzheimer’s disease, vascular dementia, and other/mixed dementia. Inverse probability of treatment weighting (IPTW) was performed to minimize the impact on dementia risk due to the imbalanced baseline characteristics. After a median follow-up period of 6.6 years, 8704 events of new-onset dementia occurred. Among all AF patients developing dementia, 73% were classified as having Alzheimer’s disease, 16% as having vascular dementia, and 11% as having other/mixed dementia. The cumulative incidence of dementia in AF patients was higher than those without AF (log-rank test: P < 0.001 for both before and after IPTW). In patients with AF undergoing catheter ablation, the total dementia risk decreased significantly [P = 0.015, hazard ratio (HR): 0.74, 95% confidence interval (CI): 0.58–0.94] after multivariable adjustment, but not for the subtype of vascular dementia (P = 0.59, HR: 0.86, 95% CI: 0.49–1.50). Patients with AF have a higher incidence of all types of dementia, including Alzheimer’s disease, vascular dementia, and a mixed type of dementia. Alzheimer’s disease is less likely to occur in patients with AF undergoing catheter ablation.

25 February 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
YHYu-Yu Hsiao
Yu-Yu Hsiao
Yun-Yu ChenYun-Yu Chen
Yun-Yu Chen
MKMing-Jen Kuo
Ming-Jen Kuo
YCYu-Shan Chien
Yu-Shan Chien
GLGuan-Yi Li
Guan-Yi Li
SCShih-Ann Chen
Shih-Ann Chen
Aims: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) enhance cardiovascular outcomes in individuals with type 2 diabetes mellitus (T2DM). Whether such effects also occur in T2DM patients with atrial fibrillation (AF) remains unknown. We aimed to investigate SGLT2i use on cardiovascular outcomes in patients with concomitant AF and T2DM. Methods: Patients with both AF and T2DM were identified from TriNetX, an international electronic medical record. Participants were divided into 2 groups according to their use of SGLT2i, at a 1:1 distribution through propensity score matching (PSM). The hazard ratio (HR) for clinical outcomes was determined using multivariate Cox hazards regression model. Results: We studied 339 792 patients with AF and T2DM, with 32 945 (9.70%) SGLT2i users. Following PSM, 17 011 patients aged 68.4 ± 7.9 years were included in each group. After a 3-year follow-up, patients treated with SGLT2i showed significantly reduced risks of stroke (adjusted HR: 0.830, P < .001), dementia (adjusted HR: 0.662, P < .001), long-standing persistent AF (adjusted HR: 0.917, P < .001), heart failure (adjusted HR: 0.833, P < .001), and all-cause mortality (adjusted HR: 0.532, P < .001). Conclusion: The use of SGLT2i was associated with reduced risks of stroke, dementia, long-standing persistent AF, heart failure, and mortality in patients with both AF and T2DM. SGLT2i may be considered as a potential first-line therapy for this population.

4 December 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
YTYung-Nan Tsai
Yung-Nan Tsai
YHYa-Wen Hsiao
Ya-Wen Hsiao
TCTing-Yung Chang
Ting-Yung Chang
CLChen-Chung Liao
Chen-Chung Liao
CLChin-Yu Lin
Chin-Yu Lin
SCShih-Lin Chang
Shih-Lin Chang
This study investigated the efficacy of resveratrol in reducing ventricular arrhythmia (VA) and modulating calcium handling in a heart failure (HF) model.

Verified
Journal Article
Open access
PDF file
GLGuan-Yi Li
Guan-Yi Li
FCFa-Po Chung
Fa-Po Chung
TCTze-Fan Chao
Tze-Fan Chao
LYLin Yenn-jiang
Lin Yenn-jiang
SCShih-Lin Chang
Shih-Lin Chang
SCShih-Ann Chen
Shih-Ann Chen
Identification of sinus node dysfunction (SND) before termination of persistent AFL by catheter ablation (CA) is challenging. This study aimed to investigate the characteristics and predictors of acute and delayed SND after AFL ablation. We retrospectively enrolled 221 patients undergoing CA of persistent AFL in a tertiary referral center. Patients with SND who required a temporary pacemaker (TPM) after termination of AFL or a permanent pacemaker (PPM) during follow-up were identified. Acute SND requiring a TPM was found in 14 of 221 (6.3%) patients following successful termination of AFL. A total of 10 of the 14 patients (71.4%) recovered from acute SND. An additional 11 (5%) patients presenting with delayed SND required a PPM during follow-up, including 4 patients recovering from acute SND. Of these, 9 of these 11 patients (81.8%) underwent PPM implantation within 1 year after the ablation. In multivariable analysis, female gender and a history of hypothyroidism were associated with the requirement for a TPM following termination of persistent AFL, while older age and a history of hypothyroidism predicted PPM implantation. This study concluded that the majority of patients with acute SND still require a PPM implantation despite the initial improvement. Therefore, it is reasonable to monitor the patients closely for at least one year after AFL ablation.

17 October 2026 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
CLChiao-Chin Lee
Chiao-Chin Lee
CLChin-Yu Lin
Chin-Yu Lin
FCFa-Po Chung
Fa-Po Chung
LYLin Yenn-jiang
Lin Yenn-jiang
SCShih-Lin Chang
Shih-Lin Chang
SCShih-Ann Chen
Shih-Ann Chen
Lee CC, et al. Korean Circ J. 2027 ;57:e14. https://doi.org/10.4070/kcj.2025.0547

1 January 2026 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
JBJose Antonio L. Bautista
Jose Antonio L. Bautista
DLDanica Ann D. Leycano
Danica Ann D. Leycano
NONaomi P. Ong
Naomi P. Ong
AIAhliah E. Ibrahim
Ahliah E. Ibrahim
FCFa-Po Chung
Fa-Po Chung
LLLi-Wei Lo
Li-Wei Lo
Bautista JA, et al. Korean Circ J. 2025 Dec;56:e36. https://doi.org/10.4070/kcj.2025.0181